Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials

Oncology (Switzerland)

Volumn 88, Issue 6, 2015, Pages 345-352

  Shao, Yu Yun ^a,b   Shau, Wen Yi ^c,d   Chan, Soa Yu ^a   Lu, Li Chun ^a,b   Hsu, Chih Hung ^a,b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Departments of Oncology   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d PFIZER   (Taiwan)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Meta analysis; Sorafenib

Indexed keywords

BRIVANIB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; DRUG EFFICACY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; VIROLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE III AS TOPIC; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84930272895     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000369559     Document Type: Article

References (27)

1. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
4. Donato F, Tagger A, Chiesa R, Ribero ML, Tomasoni V, Fasola M, Gelatti U, Portera G, Boffetta P, Nardi G: Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: A case-control study in Italy. Brescia HCC Study. Hepatology 1997; 26: 579-584.
5. Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044.
6. el-Serag HB: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87-107, vi.
7. Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127:S5-S16.
8. Morgan TR, Mandayam S, Jamal MM: Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127:S87-96.
9. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J: Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120: 1763-1773.
10. Bluteau O, Beaudoin JC, Pasturaud P, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J: Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene 2002; 21: 1225-1232.
11. Lee CF, Ling ZQ, Zhao T, Lee KR: Distinct expression patterns in hepatitis B virus-and hepatitis C virus-infected hepatocellular carcinoma. World J Gastroenterol 2008; 14: 6072-6077.
12. Lambert MP, Paliwal A, Vaissiere T, Chemin I, Zoulim F, Tommasino M, Hainaut P, Sylla B, Scoazec JY, Tost J, Herceg Z: Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 2011; 54: 705-715.
13. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S: Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49: 1098-1112.
14. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012; 57: 821-829.
15. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR: Introduction to Meta-Analysis. Chichester, Wiley, 2008.
16. Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Yang TS, Tak WY, Pan H, Yu S, Xu J, Fang F, Zou J, Lentini G, Voliotis D, Kang YK: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 2012; 48: 1452-1465.
17. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Lowenthal SP, Lanzalone S, Yang L, Lechuga MJ, Raymond E: Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31: 4067-4075.
18. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Avina J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31: 3517-3524.
19. Shao YY, Lin ZZ, Hsu CH, Cheng AL: Impact of viral etiology on the outcomes of patients with advanced hepatocellular carcinoma enrolled in prospective clinical trials for systemic therapy. Am Soc Clin Oncol Gastrointest Cancers Symposium, Orlando, 2010, abstract No 163.
20. Chen CH, Huang GT, Yang PM, Chen PJ, Lai MY, Chen DS, Wang JD, Sheu JC: Hepatitis B-and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer 2006; 42: 2524-2529.
21. Shao YY, Hsu CH, Cheng AL: Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer 2013; 2: 93-107.
22. Peixoto RD, Renouf DJ, Gill S, Cheung WY, Lim HJ: Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. J Gastrointest Oncol 2014; 5: 259-264.
23. Shao YY, Hsieh MS, Y. HC, Chang YL, Hsu CH, Cheng AL: Hepatitis C virus related advanced hepatocellular carcinoma has stronger vascular endothelial growth factor expression than hepatitis B virus related advanced HCC (abstract). J Clin Oncol 2013; 31(suppl): 4115.
24. Aoki H, Hayashi J, Moriyama M, Arakawa Y, Hino O: Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1. J Virol 2000; 74: 1736-1741.
25. Giambartolomei S, Covone F, Levrero M, Balsano C: Sustained activation of the Raf/MEK/ Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene 2001; 20: 2606-2610.
26. Burckstummer T, Kriegs M, Lupberger J, Pauli EK, Schmittel S, Hildt E: Raf-1 kinase associates with hepatitis C virus NS5A and regulates viral replication. FEBS Lett 2006; 580: 575-580.
27. O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM: Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2011; 29: 2350-2356.